Holen Sie sich die Stockscreener-App
20.91
3.62%
0.73
Handel nachbörslich:
20.91
Amphastar Pharmaceuticals Inc Aktie (AMPH) Neueste Nachrichten
Is It Too Late to Buy Amphastar Pharmaceuticals Inc (AMPH) After 3.6% Rally? GF Value Says Undervalued - GuruFocus
Lead Independent Director Richard Prins Sold A Bunch Of Shares In Amphastar Pharmaceuticals - simplywall.st
Amphastar Pharmaceuticals (AMPH) Director Richard Prins Sells 7, - GuruFocus
Richard Prins Sells 7,973 Shares of Amphastar Pharmaceuticals (NASDAQ:AMPH) Stock - marketbeat.com
Amphastar director Richard Prins disposes of shares valued at $161,851 By Investing.com - Investing.com South Africa
Amphastar director Richard Prins disposes of shares valued at $161,851 - Investing.com
Director Richard Prins sells 7,973 Amphastar (AMPH) shares at $20.30 - Stock Titan
Amphastar CFO William Peters sells $183,886 in company stock - Investing.com
Enterprise value to EBITDA forward of Amphastar Pharmaceuticals, Inc. – MUN:29A - TradingView
Amphastar Pharmaceuticals (NASDAQ:AMPH) CFO William Peters Sells 8,180 Shares - marketbeat.com
Amphastar (AMPH) CFO exercises options and sells 8,180 shares in 10b5-1 trade - Stock Titan
AMPH (AMPH) schedules Rule 144 stock sale tied to RSU vesting - Stock Titan
Amphastar Pharmaceuticals, Inc. (NASDAQ:AMPH) Receives Average Recommendation of "Reduce" from Analysts - marketbeat.com
Weekly Recap: Amphastar Q2 growth, $100M BAQSIMI and IMS FDA warning - TradingView
Results: Amphastar Pharmaceuticals, Inc. Exceeded Expectations And The Consensus Has Updated Its Estimates - moomoo.com
Amphastar Pharmaceuticals (AMPH) Stock Rebound Meets Margin Pressure And Valuation Gap - Sahm
Amphastar Pharmaceuticals (NASDAQ:AMPH) Upgraded by Wall Street Zen to "Strong-Buy" Rating - marketbeat.com
Amphastar Pharmaceuticals, Inc. SEC Filing (Aug 7, 2026) - Stock Titan
Amphastar Pharmaceuticals (NASDAQ:AMPH) Price Target Cut to $20.00 by Analysts at Piper Sandler - marketbeat.com
Wells Fargo & Company Increases Amphastar Pharmaceuticals (NASDAQ:AMPH) Price Target to $20.00 - MarketBeat
Amphastar Pharmaceuticals (NASDAQ:AMPH) Shares Gap Up After Strong Earnings - MarketBeat
Amphastar Pharmaceuticals (NASDAQ:AMPH) Releases Quarterly Earnings Results, Beats Expectations By $0.29 EPS - MarketBeat
Compared to Estimates, Amphastar (AMPH) Q2 Earnings: A Look at Key Metrics - Yahoo Finance
Amphastar Pharmaceuticals (AMPH) Q2 Earnings and Revenues Top Estimates - Yahoo Finance
Amphastar Pharmaceuticals Q2 Earnings Call Highlights - Yahoo Finance
Amphastar Pharmaceuticals, Inc. reports results for the quarter ended June 30Earnings Summary - TradingView
Amphastar Pharmaceuticals (NASDAQ:AMPH) Posts Better-Than-Expected Sales In Q2 CY2026 - Yahoo Finance
Amphastar Pharmaceuticals (NASDAQ: AMPH) Q2 revenue rises 5% with margin gains - Stock Titan
Amphastar Pharmaceuticals Reports Financial Results for the Three Months Ended June 30, 2026 - Arizona Daily Star
Pacer Advisors Inc. Buys 83,739 Shares of Amphastar Pharmaceuticals, Inc. $AMPH - MarketBeat
What To Expect From Amphastar Pharmaceuticals’s (AMPH) Q2 Earnings - The Globe and Mail
Amphastar Pharmaceuticals, Inc. $AMPH Shares Bought by Dimensional Fund Advisors LP - MarketBeat
Amphastar Pharmaceuticals, Inc. (AMPH): Investor Outlook Reveals 8.80% Upside Potential - DirectorsTalk Interviews
Arrowstreet Capital Limited Partnership Has $6.37 Million Stock Position in Amphastar Pharmaceuticals, Inc. $AMPH - MarketBeat
Analysts Estimate Amphastar Pharmaceuticals (AMPH) to Report a Decline in Earnings: What to Look Out for - Yahoo Finance
Amphastar Pharmaceuticals to Release Second Quarter Earnings and Hold Conference Call on August 6, 2026 - TradingView
Amphastar Pharmaceuticals Inc (AMPH) Cash Flow - TradingKey
Amphastar Pharmaceuticals Inc (AMPH) Institutional Confidence - TradingKey
Rice Hall James & Associates LLC Increases Position in Amphastar Pharmaceuticals, Inc. $AMPH - MarketBeat
Amphastar Pharmaceuticals Inc (AMPH) Shareholder Structure: Major Shareholders & Institutional Holdings - TradingKey
Amphastar Pharmaceuticals Inc (AMPH) Dividends & Stock Splits: Historical Payouts and Event Timeline - TradingKey
Amphastar Pharmaceuticals Inc (AMPH) Risk Assessment: Volatility, Financial Risk & Investment Risk - TradingKey
Amphastar Pharmaceuticals Inc (AMPH) Financial Health: Profitability & Balance Sheet Analysis - TradingKey
TradingKey - TradingKey
AMPH|Amphastar Pharmaceuticals Inc|Price:19.180|Chg%:+0.460 - TradingKey
Amphastar Pharmaceuticals Inc - TradingKey
AMPH|Amphastar Pharmaceuticals Inc|Price:18.720|Chg%:-0.150 - TradingKey
Amphastar Pharmaceuticals, Inc. $AMPH Shares Sold by Epoch Investment Partners Inc. - MarketBeat
Amphastar Pharmaceuticals Inc (AMPH) Q4 2023 Earnings ReportResults, Call & Slides - TipRanks
Amphastar Pharmaceuticals, Inc. (AMPH) Stock Forecasts - Yahoo! Finance Canada
Amphastar Pharmaceuticals Inc (AMPH) Q1 2024 Earnings ReportResults, Call & Slides - TipRanks
Amphastar Pharmaceuticals Inc (AMPH) Q1 2025 Earnings ReportResults, Call & Slides - TipRanks
Amphastar Pharmaceuticals Inc (AMPH) Q3 2024 Earnings ReportResults, Call & Slides - TipRanks
Amphastar Pharmaceuticals Inc (AMPH) Q3 2025 Earnings ReportResults, Call & Slides - TipRanks
Amphastar Pharmaceuticals, Inc. (AMPH) stock price, news, quote and history - Yahoo Finance Australia
Two Years to Build or Pay 200% — Which US Pharma Stocks Win? - Sahm
AMPH5896384 Bond Profile — Key Metrics - TradingView
AMPH5896384 Bond Coupon Profile — Rate & Payments - TradingView
Amphastar Pharmaceuticals (NASDAQ:AMPH) Upgraded by Zacks Research to "Hold" Rating - MarketBeat
Quantedge Capital Pte Ltd Sells 78,200 Shares of Amphastar Pharmaceuticals, Inc. $AMPH - MarketBeat
US3209RAB9 Bond Coupon Profile — Rate & Payments - TradingView
US3209RAB9 Bond Profile — Key Metrics - TradingView
Amphastar Pharmaceuticals, Inc. (AMPH): Investor Outlook and Growth Potential with 12% Upside - DirectorsTalk Interviews
Amphastar Pharmaceuticals (NASDAQ:AMPH) Screens as a High-Quality Stock with Deep Value Appeal - ChartMill
Amphastar Pharmaceuticals, Inc. (NASDAQ:AMPH) Given Average Recommendation of "Reduce" by Brokerages - MarketBeat
0.79%
5.15%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):